Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain

Belantamab-mafodotin (belamaf) is a novel antibody-drug conjugate targeting B-cell maturation antigen that showed anti-myeloma activity in patients with relapsed and refractory multiple myeloma (RRMM). We performed an observational, retrospective, and multicenter study aimed to assess the efficacy a...

Descripción completa

Detalles Bibliográficos
Autores: de la Rubia Comos, Javier, Alonso, R., Clavero, María Esther, Askari, Elham, García, Alfonso, Antón, Cristina, Fernández, Margarita, Escalante, Fernando, García, Ana, Ríos-Tamayo, Rafael, Conesa, Venancio, Bermúdez, María Arancha, Merchán, Beatriz, Velasco, Alberto E., Blanchard, María Jesús, Sampol, Antonia, Gainza, Eukene, Hernández, Prisma Montserrat, Alegre, Adrián
Tipo de recurso: artículo
Fecha de publicación:2023
País:España
Institución:Universidad Católica de Valencia San Vicente Mártir
Repositorio:RIUCV. Repositorio de la Universidad Católica de Valencia San Vicente Mártir
Idioma:inglés
OAI Identifier:oai:riucv.ucv.es:20.500.12466/5104
Acceso en línea:http://hdl.handle.net/20.500.12466/5104
Access Level:acceso abierto
Palabra clave:Belantamab mafodotin
Multiple myeloma
Relapse
Refractory
Treatment
3201.01 Oncología
Descripción
Sumario:Belantamab-mafodotin (belamaf) is a novel antibody-drug conjugate targeting B-cell maturation antigen that showed anti-myeloma activity in patients with relapsed and refractory multiple myeloma (RRMM). We performed an observational, retrospective, and multicenter study aimed to assess the efficacy and safety of single-agent belamaf in 156 Spanish patients with RRMM. The median number of prior therapy lines was 5 (range, 1–10), and 88% of patients were triple-class refractory. Median follow-up was 10.9 months (range, 1–28.6). The overall response rate was 41.8% (≥CR 13.5%, VGPR 9%, PR 17.3%, MR 2%). The median progression-free survival was 3.61 months (95% CI, 2.1–5.1) and 14.47 months (95% CI, 7.91–21.04) in patients achieving at least MR (p < 0.001). Median overall survival in the entire cohort and in patients with MR or better was 11.05 months (95% CI, 8.7–13.3) and 23.35 (NA-NA) months, respectively (p < 0.001). Corneal events (87.9%; grade ≥ 3, 33.7%) were the most commonly adverse events, while thrombocytopenia and infections occurred in 15.4% and 15% of patients, respectively. Two (1.3%) patients discontinued treatment permanently due to ocular toxicity. Belamaf showed a noticeably anti-myeloma activity in this real-life series of patients, particularly among those achieving MR or better. The safety profile was manageable and consistent with prior studies.

Similares en LA Referencia